此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Gut Microbiome Characteristics and Neurodevelopmental Functioning in Children With Autism Spectrum Disorder (GAIN-ASD)

2026年6月12日 更新者：Jeevarathinam Thirumalai、Saveetha University

Association Between Gut Microbiome Characteristics and Neurodevelopmental Functioning in Children With Autism Spectrum Disorder: A Multidomain Investigation of the Gut-Motor Axis

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition that affects communication, behavior, sensory processing, and daily functioning. Recent research suggests that the gut microbiome, the community of microorganisms living in the gastrointestinal tract, may influence brain development and function through the gut-brain and gut-motor axes. Alterations in gut microbiome characteristics have been reported in children with ASD and may be associated with differences in neurodevelopmental outcomes.

This observational study aims to investigate the association between gut microbiome characteristics and neurodevelopmental functioning in children with ASD. The study will evaluate multiple domains of functioning, including motor performance, sensory processing, behavior, cognition, sleep, and participation in daily activities. Gut microbiome characteristics will be assessed using stool sample analysis, and neurodevelopmental outcomes will be measured using standardized assessments and validated questionnaires.

The findings of this study may improve understanding of the relationship between the gut microbiome and neurodevelopmental functioning in children with ASD and provide insights into the role of the gut-motor axis in shaping functional outcomes. This knowledge may support future research and contribute to the development of more personalized approaches to assessment and rehabilitation in ASD.

研究概览

地位

尚未招聘

条件

详细说明

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by impairments in social communication, restricted and repetitive behaviors, sensory processing differences, and variable functional abilities across developmental domains. Increasing evidence suggests that the gut microbiome may play a role in neurodevelopment through bidirectional communication pathways linking the gastrointestinal system and the central nervous system. These interactions, commonly described as the gut-brain axis, have been implicated in behavioral, cognitive, sensory, and motor processes. More recently, the concept of the gut-motor axis has emerged, highlighting potential relationships between gut microbial composition and motor functioning.

Several studies have reported alterations in gut microbiome composition among children with ASD compared with typically developing peers. However, existing research has largely focused on autism symptom severity, behavioral manifestations, or gastrointestinal symptoms, while the association between gut microbiome characteristics and broader neurodevelopmental functioning remains insufficiently explored. Furthermore, few studies have examined multiple functional domains simultaneously within a rehabilitation framework.

The present study aims to investigate the association between gut microbiome characteristics and neurodevelopmental functioning in children with ASD. A multidomain assessment approach will be employed to evaluate neurodevelopmental outcomes encompassing motor performance, sensory processing, behavioral function, cognitive functioning, sleep, and participation in daily activities. Gut microbiome characteristics will be assessed through stool sample analysis using established microbiological methods. Neurodevelopmental outcomes will be evaluated using standardized assessments and validated caregiver-reported instruments.

By examining the relationship between gut microbiome characteristics and multidimensional functional outcomes, this study seeks to enhance understanding of the gut-motor axis in ASD and identify potential microbiome-related factors associated with neurodevelopmental functioning. The findings may contribute to the growing body of evidence on microbiome-neurodevelopment interactions and inform future translational and rehabilitation research in children with ASD.

研究类型

观察性的

注册 (估计的)

600

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 印度
    • Tamil Nadu
      • Chennai、Tamil Nadu、印度、602 105
        • Saveetha Medical College and Hospital
        • 接触：

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population will consist of children aged 3 to 12 years with a confirmed diagnosis of Autism Spectrum Disorder (ASD) who are receiving care at participating pediatric rehabilitation, developmental, neurology, psychiatry, and autism care centers. Eligible participants will undergo stool sample collection for gut microbiome analysis and multidomain neurodevelopmental assessment, including evaluation of autism severity, gross motor function, sensory processing, cognitive functioning, behavioral function, sleep, participation, quality of life, gastrointestinal symptoms, dietary intake, and anthropometric nutritional status. Written informed consent will be obtained from parents or legal guardians prior to participation.

描述

Inclusion Criteria:

  • Children aged 3 to 12 years
  • Clinical diagnosis of Autism Spectrum Disorder (ASD) according to DSM-5/ICD criteria and confirmed from medical records or specialist assessment
  • Stable clinical status at the time of enrollment
  • Parent/legal guardian willing to provide written informed consent
  • Child able to undergo stool sample collection and neurodevelopmental assessments
  • Parent/caregiver able to complete questionnaires and provide dietary and medical history

Exclusion Criteria:

  • Use of systemic antibiotics, probiotics, prebiotics, synbiotics, or bowel-cleansing agents within the previous 4-12 weeks before stool collection
  • Presence of acute gastrointestinal infection or acute febrile illness at the time of assessment
  • Known chronic gastrointestinal disorders that may independently alter the gut microbiome, such as inflammatory bowel disease, celiac disease, short bowel syndrome, or chronic intestinal malabsorption
  • Major neurological, genetic, or metabolic disorders other than ASD that may independently affect neurodevelopment
  • Current use of medications known to significantly affect gut microbiota or bowel motility, if clinically relevant to your protocol
  • Inability to provide stool sample or complete the required assessments
  • Refusal of consent by parent/legal guardian

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

队列和干预

团体/队列
Children With Autism Spectrum Disorder
Children diagnosed with Autism Spectrum Disorder (ASD) who meet the study eligibility criteria. Participants will provide stool samples for gut microbiome analysis and undergo multidomain neurodevelopmental assessment.
Typically Developing Children
Age- and sex-matched typically developing children without a diagnosis of Autism Spectrum Disorder or other neurodevelopmental disorders. Participants will provide stool samples for gut microbiome analysis and undergo neurodevelopmental assessment for comparison with the ASD cohort.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Gut Microbiome Diversity and Composition
大体时间：Baseline (single stool sample collected at study enrollment)
Gut microbiome characteristics will be assessed from stool samples using 16S rRNA gene sequencing. Primary microbiome outcomes will include alpha diversity indices (Shannon Diversity Index, Simpson Diversity Index, and Chao1 Richness Index), beta diversity measures, and the relative abundance of bacterial taxa. These measures will be used to characterize gut microbial diversity and composition in children with Autism Spectrum Disorder.
Baseline (single stool sample collected at study enrollment)
Indian Scale for Assessment of Autism
大体时间：Baseline
Autism severity will be assessed using the Indian Scale for Assessment of Autism (ISAA). The ISAA total score ranges from 40 to 200, with higher scores indicating greater autism symptom severity (worse outcomes) and lower scores indicating less severe autism-related impairments (better outcomes). The total score will be used to determine the severity of autism symptoms and examine associations with gut microbiome characteristics.
Baseline

次要结果测量

结果测量
措施说明
大体时间
Gross Motor Function Measure-88 Total Score
大体时间：Baseline
Gross motor function will be assessed using the Gross Motor Function Measure-88 (GMFM-88). The GMFM-88 evaluates gross motor performance across five dimensions: lying and rolling, sitting, crawling and kneeling, standing, and walking, running, and jumping. Scores range from 0 to 100%, with higher scores indicating better gross motor function (better outcomes) and lower scores indicating poorer gross motor function (worse outcomes). Total scores and dimension scores will be used to evaluate motor performance and its association with gut microbiome characteristics.
Baseline
Gastrointestinal Symptom Severity Score
大体时间：Baseline
Gastrointestinal symptoms, including constipation, diarrhea, abdominal pain, and bloating, will be assessed using a structured Gastrointestinal Symptom Questionnaire (total score range: 0-100, with higher scores indicating greater gastrointestinal symptom severity). Stool consistency will be assessed using the Bristol Stool Form Scale (BSFS), a 7-point scale ranging from Type 1 (separate hard lumps, indicating severe constipation) to Type 7 (entirely liquid stool, indicating severe diarrhea), with higher scores reflecting looser stool consistency.
Baseline
Strengths and Difficulties Questionnaire Total Difficulties Score
大体时间：Baseline
Emotional and behavioral difficulties will be assessed using the Strengths and Difficulties Questionnaire (SDQ) Total Difficulties Score. The total difficulties score ranges from 0 to 40, with higher scores indicating greater emotional and behavioral difficulties (worse outcomes) and lower scores indicating fewer difficulties (better outcomes).
Baseline
Patient-Reported Outcomes Measurement Information System Sleep Disturbance Scale Score
大体时间：Baseline
Sleep disturbance will be assessed using the Patient-Reported Outcomes Measurement Information System Sleep Disturbance Scale (PROMIS Sleep Disturbance Scale). The scale evaluates perceived sleep quality, sleep difficulties, sleep satisfaction, and sleep-related concerns. Scores range from 8 to 40, with higher scores indicating greater sleep disturbance (worse sleep outcomes) and lower scores indicating better sleep quality. Associations between sleep disturbance and gut microbiome characteristics will be examined.
Baseline
Participation Questionnaire for Preschoolers With Autism Score
大体时间：Baseline
Participation will be assessed using the Participation Questionnaire for Preschoolers with Autism (PPA). The questionnaire evaluates participation in home, preschool, community, play, and social activities. The total score ranges from 0 to 100, with higher scores indicating greater participation in everyday activities (better outcomes) and lower scores indicating reduced participation. Associations between participation outcomes and gut microbiome characteristics will be examined.
Baseline
Sensory Experiences Questionnaire Total Score
大体时间：Baseline
Sensory processing will be assessed using the Sensory Experiences Questionnaire Version 2.1 (SEQ-2.1), a caregiver-reported measure designed to evaluate sensory experiences in children with Autism Spectrum Disorder. The questionnaire assesses sensory hyperreactivity, hyporeactivity, and sensory-seeking behaviors across multiple sensory modalities. The total score ranges from 0 to 145, with higher scores indicating greater sensory processing difficulties (worse outcomes) and lower scores indicating fewer sensory processing difficulties. Associations between sensory processing outcomes and gut microbiome characteristics will be examined.
Baseline
PROMIS Parent Proxy Cognitive Function Score
大体时间：Baseline
Cognitive functioning will be assessed using the Patient-Reported Outcomes Measurement Information System Parent Proxy Cognitive Function Measure (PROMIS Parent Proxy Cognitive Function Measure). The instrument evaluates caregiver-reported difficulties related to attention, memory, concentration, learning, and thinking abilities in children. Scores are reported as standardized T-scores (mean = 50, standard deviation = 10), with higher scores indicating better perceived cognitive functioning (better outcomes) and lower scores indicating poorer cognitive functioning (worse outcomes). Associations between cognitive function and gut microbiome characteristics will be examined.
Baseline
Dietary Intake Score
大体时间：Baseline
Dietary intake will be assessed using parent proxy-reported 24-hour dietary recalls collected on 2-3 non-consecutive days, including at least one weekend day, using the multiple-pass recall method. Information on daily energy intake (kcal/day), macronutrient intake (g/day), dietary fiber intake (g/day), and consumption of key food groups (servings/day) will be recorded. A supplementary Food Frequency Questionnaire (FFQ) will assess the habitual consumption of fruits and vegetables, whole grains, fermented foods, sugar-sweetened beverages, and ultra-processed foods. Composite Healthy Diet Score and Unhealthy Diet Score will be derived to characterize dietary patterns, with higher Healthy Diet Scores indicating healthier dietary patterns and higher Unhealthy Diet Scores indicating less healthy dietary patterns. Dietary intake variables will be used as covariates in analyses examining associations between gut microbiome characteristics and neurodevelopmental functioning in children with
Baseline
Pediatric Quality of Life Inventory Total Score
大体时间：Baseline
Quality of life will be assessed using the Pediatric Quality of Life Inventory (PedsQL). The instrument evaluates physical, emotional, social, and school functioning in children. Scores range from 0 to 100, with higher scores indicating better health-related quality of life (better outcomes) and lower scores indicating poorer health-related quality of life (worse outcomes). Associations between quality of life and gut microbiome characteristics will be examined in children with Autism Spectrum Disorder.
Baseline
Anthropometric Nutritional Status Score
大体时间：Baseline
Anthropometric nutritional status will be assessed using standardized measurements of height (cm), weight (kg), and body mass index (BMI; kg/m²). Age- and sex-specific z-scores for weight-for-age, height-for-age, BMI-for-age, and weight-for-height (where applicable) will be calculated according to the World Health Organization (WHO) Child Growth Standards and Growth Reference charts. For z-score indicators, a value of 0 represents the WHO reference population median, positive values indicate measurements above the reference median, and negative values indicate measurements below the reference median. Nutritional status categories, including undernutrition, normal nutritional status, overweight, and obesity, will be determined using WHO classification criteria. Associations between anthropometric nutritional status and gut microbiome characteristics will be examined in children with Autism Spectrum Disorder.
Baseline
Body Mass Index-for-Age Z-Score
大体时间：Baseline
Body mass index (BMI) will be calculated as weight (kg) divided by height squared (m²). BMI-for-age z-scores will be derived using World Health Organization (WHO) age- and sex-specific growth references. A z-score of 0 represents the WHO reference population median, positive z-scores indicate BMI values above the reference median, and negative z-scores indicate BMI values below the reference median. BMI-for-age z-scores will be used to evaluate nutritional status and examine their association with gut microbiome characteristics and neurodevelopmental functioning.
Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Saveetha University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2026年12月31日

研究注册日期

首次提交

2026年6月9日

首先提交符合 QC 标准的

2026年6月9日

首次发布 (实际的)

2026年6月15日

研究记录更新

最后更新发布 (实际的)

2026年6月16日

上次提交的符合 QC 标准的更新

2026年6月12日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 079/06/2026/ISRB/FSR/SIBMS

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

未定

IPD 计划说明

Individual participant data (IPD) may be shared upon reasonable request following publication of the study findings, subject to institutional policies, ethical approval requirements, participant confidentiality protections, and applicable data-sharing agreements. A final decision regarding IPD sharing will be made after completion of the study and in accordance with institutional and regulatory guidelines.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅